about
In vitro maturation (IVM) of oocytes recovered from ovariectomy specimens in the laboratory: a promising "ex vivo" method of oocyte cryopreservation resulting in the first report of an ongoing pregnancy in EuropeHuman cumulus-enclosed germinal vesicle oocytes from early antral follicles reveal heterogeneous cellular and molecular features associated with in vitro maturation capacityFertility preservation in women with cancer.Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and "freeze-all": in-depth analysis of genetic predisposition.Creating a Global Community of Practice for Oncofertility.The effect of ovarian puncture on the endocrine profile of PCOS patients who undergo IVMThe definition of IVM is clear-variations need defining.Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?What is the optimal duration of progesterone administration before transferring a vitrified-warmed cleavage stage embryo? A randomized controlled trial.Chromosome constitution of human embryos generated after in vitro maturation including 3-isobutyl-1-methylxanthine in the oocyte collection medium.Effect of ovarian stimulation and oocyte retrieval on reproductive outcome in oocyte donors.An improved IVM method for cumulus-oocyte complexes from small follicles in polycystic ovary syndrome patients enhances oocyte competence and embryo yield.Serum reproductive hormone levels and ultrasound findings in female offspring after intracytoplasmic sperm injection: first results.Frozen-thawed embryo transfers in natural cycles with spontaneous or induced ovulation: the search for the best protocol continues.Corifollitropin alfa followed by hpHMG in GnRH agonist protocols. Two prospective feasibility studies in poor ovarian respondersSurvey of Fertility Preservation Options Available to Patients With Cancer Around the GlobeSurvey of Third-Party Parenting Options Associated With Fertility Preservation Available to Patients With Cancer Around the GlobeCumulative Live Birth Rates Following Stimulation With Corifollitropin Alfa Compared With hp-hMG in a GnRH Antagonist Protocol in Poor Ovarian RespondersLimited ability of circulating anti-Müllerian hormone to predict dominant follicular recruitment in PCOS women treated with clomiphene citrate: a comparison of two different assaysCumulative live birth rates after IVF in patients with polycystic ovaries: phenotype mattersCumulus-corona gene expression analysis combined with morphological embryo scoring in single embryo transfer cycles increases live birth after fresh transfer and decreases time to pregnancyAberrant endometrial steroid receptor expression in in-vitro maturation cycles despite hormonal luteal support: A pilot studyIn vitro maturation (IVM) of oocytes in patients with resistant ovary syndrome and in patients with repeated deficient oocyte maturationObstetric and neonatal outcome of ART in patients with polycystic ovary syndrome: IVM of oocytes versus controlled ovarian stimulationOocyte donation in donors with levonorgestrel intrauterine device: a good match?Live births after oocyte in vitro maturation with a prematuration step in women with polycystic ovary syndromePituitary suppression protocol among Bologna poor responders undergoing ovarian stimulation using corifollitropin alfa: does it play any role?Modified natural cycle IVF versus conventional stimulation in advanced-age Bologna poor respondersBiphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral folliclesICSI does not offer any benefit over conventional IVF across different ovarian response categories in non-male factor infertility: a European multicenter analysisA follow-up survey on the reproductive intentions and experiences of women undergoing planned oocyte cryopreservationRare genetic variants potentially involved in ovarian hyperstimulation syndromeFrozen-warmed blastocyst transfer after 6 or 7 days of progesterone administration: impact on live birth rate in hormone replacement therapy cycles
P50
Q28265984-5E668B34-DE61-4253-8A9F-5B0A9FB4B9A8Q29027343-97DA43F7-A0F6-4335-9715-AD86EFBE00ADQ34729392-B7E7FC9A-A687-45DF-BDD3-BD9A0D0BA084Q35938164-04CF26D7-93FC-4689-AB82-9E9666A544E2Q36972385-962E0224-8F0F-4482-AC4E-B17BADDE6613Q37607260-491798D2-4F59-431F-8515-AD64649BE6F8Q38963451-F9FA2E71-90FD-435D-B5C1-D2D08155056CQ40151006-B371D8A1-B328-463A-8C83-3332882013BCQ40837712-C9DB5A8A-6D09-482E-9F82-C5393474CC78Q41726893-5E5AB2BF-E3A5-4E37-8A3F-99E14009A0ACQ46203165-3F53F50C-9E67-4CD0-A2C9-57B2A5E57A25Q47262868-8AC20B0F-8910-40F2-BD54-80F68D620CDCQ47418378-8FE62F12-455B-4DBF-8BD7-73D6E03C5402Q47961842-A7819A94-73CF-416F-A783-3CA8C6783987Q56971617-A5D5E3E1-445D-4ADC-9C3E-42CD7DAC5E9FQ60456249-5A5DB072-24BF-4AAB-B2A9-E2A867268EECQ60456250-34891BA7-866E-42F9-AAFD-D656DCC2A667Q64060782-E6EE0FDA-9E11-4AB9-9E27-53BA30443C15Q86680574-A99A9DD2-FC2B-47B9-8C3C-BD1AF9BB9757Q88736911-9805AF5A-9036-46AE-BBA8-6F3443325488Q90975688-F5587D5A-5BAF-4BA2-ADE6-533CE91EFC6EQ91525207-A7E12640-8C5E-43DD-ACCF-D8C540DE4A3EQ91604433-247FCF42-150C-41D1-984A-29CBE164391FQ92197945-381D5235-6E7C-4906-BF89-10A72B79AEB5Q92294420-7FCE2A8C-A387-4FDA-89C8-16516E3A36C3Q92418110-09BDE109-5892-4FFE-92F3-504D3E17C3EDQ92420134-A92BDA5E-E876-4420-A1B1-F64306AB2383Q92429605-982B87FC-DDBD-4FAC-A309-F25AB09FCFF0Q92536476-E042856F-2F7B-4D15-8B43-AB9731E312D0Q92805443-47D714E9-D326-4252-AF59-C827E71DD09DQ92951002-F4C2E263-0765-45C5-8E5C-0C2D81FC8AFEQ93358265-B78A55EC-2717-44D1-909E-0A868578B4F2Q96586294-43BB9BA9-ADA6-49E0-8E49-8574BC1E777D
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Michel de Vos
@en
Michel de Vos
@nl
type
label
Michel de Vos
@en
Michel de Vos
@nl
prefLabel
Michel de Vos
@en
Michel de Vos
@nl
P31
P496
0000-0001-5019-5924